G. Pavlakou

A Multicenter Phase II Study of the Combination of Irinotecan and Gemcitabine in Previously Treated Patients with Small-Cell Lung Cancer

V. Georgoulias, K. Syrigos, S. Agelaki, 2004, Oncology.

A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC

V. Georgoulias, I. Varthalitis, A. Pallis, 2011, Cancer Chemotherapy and Pharmacology.

The effects of osmotic challenge on bronchial responsiveness to methacholine in non-asthmatic subjects.

P. Rees, G. Pavlakou, D. Antoniou, 1990, The European respiratory journal.

Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.

Ioannis Karydis, I. Karydis, G. Stathopoulos, 2006, Lung cancer.

A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer.

V. Georgoulias, S. Agelaki, I. Varthalitis, 2009, Lung cancer.

Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.

S. Agelaki, D. Mavroudis, V. Georgoulias, 2010, Anticancer research.

Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.

D. Mavroudis, V. Georgoulias, M. Ignatiadis, 2005, Clinical lung cancer.

Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study.

S. Agelaki, D. Mavroudis, V. Georgoulias, 2003, Lung cancer.

Docetaxel versus docetaxel/cisplatin in patients with advanced non-small-cell lung cancer: preliminary analysis of a multicenter, randomized phase III study.

V. Georgoulias, N. Samaras, A. Pallis, 2003, Clinical lung cancer.

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

S. Agelaki, V. Georgoulias, K. Syrigos, 2010, BMC Cancer.

Pooled Analysis of Elderly Patients with Non-small Cell Lung Cancer Treated with Front Line Docetaxel/Gemcitabine Regimen: The Hellenic Oncology Research Group Experience

S. Agelaki, V. Georgoulias, I. Boukovinas, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.